Tasigna Shows Promise in Systemic Sclerosis

Author: Pam Harrison
Date Published: August-2015
Source: MedPage Today

Patients with early diffuse systemic sclerosis (SSc) showed signs of significant improvement after 6 and 12 months of treatment with nilotinib (Tasigna), according to an open-label, pilot study. Ten patients with early and active diffuse SSc, whose median disease duration was 0.7 years and whose modified Rodnan Skin Scores were worsening in the month prior to the initiation of treatment, received nilotinib, for 12 months, reported Jessica K. Gordon, MD, of the Hospital for Special Surgery in New York City, and colleagues